Stockscreener 앱 받기
47.94
3.37%
1.6546
Bristol Myers Squibb Co 주식(BMY)의 최신 뉴스
Bristol Myers Squibb (BMY) Collaborates on Alzheimer's Drug Deve - GuruFocus
Bristol-Myers (NYSE:BMY) Squibb Dividend Update Reflects Steady Healthcare NYSE Composite - Kalkine Media
Bristol-Myers Squibb (NYSE:BMY) Declares US$0.62 Common and US$0.50 Preferred Dividends - Yahoo
BioNTech and Bristol Myers Squibb Collaborate on BNT327, a PD-L1xVEGF-A Bispecific Antibody for Tumor Treatment - geneonline.com
Bristol Myers Squibb to present positive new data on lymphoma treatment - Pharmafile
Bristol Myers Squibb (BMY) Loses Key Executive to Climb Bio | BM - GuruFocus
Bristol Myers Squibb (BMY) Loses Key Executive to Climb Bio | BMY Stock News - GuruFocus
Global Drugmakers Tap Chinese Biotech for Novel Cancer Therapies - Caixin Global
Bristol Myers Squibb declares quarterly dividend of $0.62 per share By Investing.com - Investing.com Nigeria
Bristol Myers Squibb Announces Dividend - marketscreener.com
Bristol-Myers Expands in Cancer Care With $1.35B OncoACP3 Deal - Insider Monkey
Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - The Motley Fool
BioNTech and Bristol Myers Squibb Partner to Develop PD-L1xVEGF-A Bispecific Antibody for Cancer Therapy - geneonline.com
Bristol Myers Squibb Presents Promising Blood Cancer Drug Data at EHA Congress - MSN
Bristol Myers Squibb (BMY) Shares Cross 5% Yield Mark - Nasdaq
Myocardial Infarction Market Is Booming So Rapidly 2025-2032 - openPR.com
Vanguard Health Care Fund's Strategic Moves: A Closer Look at Bristol-Myers Squibb Co - Yahoo Finance
Bristol-Myers Squibb (BMY) Announces Positive Data From the Pivotal Phase 3 POETYK PsA-1 Trial - MSN
Bristol Myers Squibb (BMY) Achieves Strong Results with Breyanzi in Lymphoma Study - GuruFocus
Bristol Myers: positive phase 2 data in lymphoma - MarketScreener
Bristol Myers (BMY) Reports Promising Results from Lymphoma Stud - GuruFocus
Schizophrenia Drugs Market Size, Share & Forecast 2025 | Major - openPR.com
Bristol-Myers Squibb (BMY) Stock Analysis: Healthcare Giant with a 14.77% Potential Upside - DirectorsTalk Interviews
Business development leadership team - Bristol Myers Squibb
BioNTech and Bristol Myers Squibb Partner to Develop PD-L1xVEGF-A Bispecific Antibody for Cancer Treatment - geneonline.com
Rockland Trust Co. Sells 20,035 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Jim Cramer on Bristol Myers: “We Need to See That Stock Back Up at $60” - Insider Monkey
BioNTech and Bristol Myers Squibb Partner to Develop Bispecific Antibody Targeting PD-L1 and VEGF-A for Tumor Treatment - geneonline.com
Bristol-Myers Squibb’s SWOT analysis: stock outlook amid Cobenfy growth and pipeline potential - Investing.com
Bristol Myers gets a key strategist with 'Team Shibs'; Idorsia to change CEOs after it 'hit a reset button' - Endpoints News
Bristol Myers (BMY) Showcases Promising New Data on Targeted Pro - GuruFocus
Bristol-Myers Promotes Attorney To Lead Corporate Affairs - Law360
BioNTech and Bristol Myers Squibb Partner to Develop BNT327 Antibody Targeting PD-L1 and VEGF-A Pathways in Tumors - geneonline.com
Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu Compared with Placebo in Adults with Psoriatic Arthritis - marketscreener.com
Bristol-Myers stock holds steady as Cantor maintains neutral rating By Investing.com - Investing.com South Africa
BMY Reports Positive Data on Sotyktu From Arthritis Study - TradingView
Bristol Myers Squibb promotes Wendy Bartie to lead corporate affairs - PR Week UK
Bristol Myers: new data to be presented in hematology - marketscreener.com
Bristol-Myers stock holds steady as Cantor maintains neutral rating - Investing.com
Bristol Myers Squibb presents protein degradation data at EHA By Investing.com - Investing.com India
Bristol Myers Squibb presents protein degradation data at EHA - Investing.com
Bristol Myers Squibb Sets Q2 2025 Earnings Date: Key Financial Results Coming July 31 - Stock Titan
Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025 - The Joplin Globe
Bristol Myers Squibb (BMY) Exceeds Market Returns: Some Facts to Consider - MSN
Bristol-Myers Squibb (NYSE:BMY) Reports Positive Phase 3 Trial Results For Sotyktu - Yahoo Finance
Bristol Myers at Goldman Sachs Conference: Strategic Insights on Growth - Investing.com Australia
Bristol Myers bolsters radiopharma portfolio with PhiloChem deal - BioPharma Dive
Transcript : Bristol-Myers Squibb Company Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10 - MarketScreener
Bristol Myers (BMY) Sees Promising Results for Sotyktu in Phase 3 Trial - GuruFocus
BioNTech and Bristol Myers Squibb Collaborate on PD-L1xVEGF-A Bispecific Antibody for Tumor Treatment - geneonline.com
Bristol-Myers Squibb To Present At Goldman Sachs Global Conference; Webcast At 10:00 AM ET - Nasdaq
Bristol Myers: positive data in psoriatic arthritis - marketscreener.com
Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis - BioSpace
FY2026 Earnings Forecast for BMY Issued By Cantor Fitzgerald - Defense World
0.10%
0.21%
자본화:
|
볼륨(24시간):